ESC Professional Premium Access

Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis

Congress Presentation

About the speaker

Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)
4 presentations
0 follower

7 more presentations in this session

Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study

Speaker: Doctor M. Abou Kaoud (Tel Aviv, IL)


Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

Speaker: Mr M. Grymonprez (Ghent, BE)


Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

Speaker: Doctor S. Deitelzweig (New Orleans, US)


Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

Speaker: Doctor S. Patel (Boston, US)


Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients

Speaker: Doctor J. Kim (Seoul, KR)


Access the full session

Oral anticoagulation in patients with atrial fibrillation

Speakers: Doctor T. Chao, Doctor M. Abou Kaoud, Mr M. Grymonprez, Doctor S. Deitelzweig, Doctor S. Patel...

About the event


ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

ESC 365 is supported by